دراسة بعض الماركرات في النساء العراقيات المريضات بسرطان الثدي

AICR American Institute of Cancer Research. Diet,

Nutrition, Physical activity and breast cancer. World

Cancer Research Fund. 2017 .Pp: 4.

Martínez-Montiel N, Anaya-Ruiz M, Pérez-Santos

M, Martínez-Contreras RD. Alternative Splicing in

Breast Cancer and the Potential Development of

Therapeutic Tools. Genes. 2017; 8 (217): 1 – 14.

Available from http://www.mdpi.com/journal/genes

DOI: 10.3390/genes8100217.

ACS American Cancer Society. Cancer Facts and

Figures2018. Atlanta. American Cancer

Society.Inc.Pp: 1, 12.

Saifullah PH, AL-Kazzaz FF, Zayzafoon NN.

Study of Malondialdehyde levels in sera, RBCs ant

tissues homogenate of Iraqi women with breast

tumors. Baghdad Sci J. 2009; 6 ( 3 ) : 553 – 562 .

Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini

A, Senkus E, et al. Clinical use of biomarkers in

breast cancer: Updated guidelines from the European

Group on Tumor Markers (EGTM) .Eur J of Cancer.

; 75: 284e – 298e. Available from http://

dx.doi.org DOI: 10.1016/j.ejca.2017.01.017.

Open Access Baghdad Science Journal P-ISSN: 2078-8665

, 18(4): 1140-1148 E-ISSN: 2411-7986

Weigel MT, Dowsett M. Current and emerging

biomarkers in breast cancer: prognosis and prediction

. EndocrRelat Cancer. 2010; 17 (1): R245 – R262.

Available fromhttp://www.endocrinology-

journals.org.DOI: 10.1677/ERC-10-0136.

Bjornstrom L, Sjoberg M . Mechanisms of Estrogen

Receptor Signaling: Convergence of Genomic and

Nongenomic Actions on Target Genes

.MolEndocrinol. 2005; 19 (4): 833 – 842. Available

from https://academic.oup.com/mend/article-

abstract/19/4/833/2741274.DOI: 10.1210/me.2004-

Yue W, Wang J-P, Li Y, Fan P, Liu G, Zhang

N, et al. Effects of estrogen on breast cancer

development: role of estrogen receptor independent

mechanisms. Int J Cancer. 2010; 127 (8): 1748

–1757. DOI: 10.1002/ijc.25207.

Micheli A, Muti P, Secreto G, Krogh V, Meneghini

E, Venturelli E, et al. Endogenous sex hormones

and subsequent breast cancer in premenopausal

women.Int.J Cancer. 2004; 112 (1):312 – 318

.Available from

https://doi.org/10.1002/ijc.20403.DOI:

1002/ijc.20403.

Majumder A, Singh M, Tyagi SC. Post-

menopausal breast cancer: from estrogen to androgen

receptor .Oncotarget. 2017; 8 (60): 102739 – 102758.

Selli C, Sims AH.Neoadjuvant Therapy for Breast

Cancer as a Model for Translational Research . Breast

Cancer: Basic and Clin Res. 2019; 13: 1- 7. DOI:

1177/1178223419829072.

Wang J, Xu B. Targeted therapeutic options and

future perspectives for HER2-positive breast cancer

.Signal Transduct Target Ther. 2019; 4 ( 34 ) : 1 –

Available from http: // doi. Org DOI:

1038/s41392-019-0069-2.

Sareyeldin RM, Gupta I, Al-Hashimi I, Al-

Thawadi HA, Al Farsi HF, Vranic S, et al. Gene

Expression and miRNAs Profiling: Function and

Regulation in Human Epidermal Growth Factor

Receptor 2 (HER2)-Positive Breast Cancer. Cancers.

; 11 (646): 1 – 20. Available from

www.mdpi.com/journal/cancers.DOI:

3390/cancers 11050646.

Furrer D, Paquet C, Jacob S, Diorio C. The

Human Epidermal Growth Factor Receptor 2 ( HER2

) as a prognostic and predictive biomarker: molecular

insights into HER2 activation and diagnostic

implications. IntechOpe. 2018; 11 – 31.Available

from http : // dx.doi.org DOI:

5772/intechopen.78271.

Wilson FR, Coombes ME, Wylie Q, Yurchenko

M, Brezden-MasleyCh, Hutton B, et al. Herceptin

(trastuzumab) in HER2-positive early breast cancer:

protocol for a systematic review and cumulative

network meta-analysis. Systematic Reviews. 2017; 6

(196): 1 – 8. Available from

https://www.crd.york.ac.uk/prospero.DOI:

1186/s13643-017-0588-2.

Mokuyasu S, Suzuki Y.Clinical Utility of Serum

Human Epidermal Growth Factor Receptor Type 2

Testing as a Marker of Therapeutic Response in

Tissue HER2-Positive Breast Cancer Patients . Int J

Cancer Clin Res. 2017; 4 ( 2 ) : 1 – 6. DOI:

23937/2378-3419/1410089.

Cianfrocca M, Goldstein LJ. Prognostic and

Predictive Factors in Early-Stage Breast Cancer.

Oncologist. 2004; 9 : 606 – 616 .

Hatem SF, Alyaqubi KJ, Al-Atrooshi SAB – W,

Alsayyid MM, Saad M, Safaa R. The Study of

HER-2/neu, ER/PR Expression Using

Immunohistochemistry (IHC) in the Iraqi Breast

Cancer.Kufa J For Veter Med Sci .2016; 7 ( 1 ): 18 –

.

Chappuis PO, Donato E, Goffin JR, Wong N,

Be´gin LR, Kapusta LR, et al. Cyclin E expression

in breast cancer: predicting germline BRCA1

mutations, prognosis and response to treatment.

Annals of Oncology.2005; 16: 735 –

Availablefrom

https://academic.oup.com/annonc/article-

abstract/16/5/735/150169.DOI:

1093/annonc/mdi149.

Hwang HC, Clurman BE. Cyclin E in normal and

neoplastic cell cycles.Oncogene.2005; 24: 2776 –

DOI: 10.1038/sj.onc.1208613.

Law ME, Corsino PE, Narayan S, Law BK.

Cyclin-Dependent Kinase Inhibitors as Anticancer

Therapeutics.Mol.Pharmacol.2015; 88: 846 –

Available from http:// dx.doi.org DOI:

1124/mol.115.099325.

Akli S, Carolyn S, Pelt V, Bui T, Multani AS,

Chang S, et al. Overexpression of the Low Molecular

Weight Cyclin E in Transgenic Mice Induces

Metastatic Mammary Carcinomas through the

Disruption of the ARF-p53 Pathway . Cancer Res .

; 67: (15) : 7212 – 7222 . Available from

http://cancerres.aacrjournals.org.DOI : 10.1158/0008-

CAN-07-0599 .

Karakas C, Biernacka A, Bui T, Sahin AA, Yi M,

Akli S, et al.CytoplasmicCyclin E and Phospho-

Cyclin - Dependent Kinase 2 Are Biomarkers of

Aggressive Breast Cancer. The Am J of Pathol. 2016;

(7): 1900 – 1912. Available from http://

dx.doi.org DOI: 10.1016/j.ajpath.2016.02.024 .

Duronio RJ, Xiong Y. Signaling pathways that

control cell proliferation. Cold Spring Harbor

perspectives in biology. 2013 Mar

;5(3):a008904.Available from

www.cshperspectives.org.DOI:

/cshperspect.a008904.

Iqbal BM, Buch A. Hormone receptor (ER, PR,

HER2/neu) status and proliferation index marker (Ki-

in breast cancers: Their onco-pathological

correlation, shortcomings and future trends. Med J

DYPatil Univ. 2016; 9 (6): 674 – 679.Available

from: http://www.mjdrdypu.org/text.asp?2016/9/6/67

/194180. DOI: 10.4103/0975-2870.194180.

Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi

M, Sahin AA, et al. Cytoplasmic Cyclin E Predicts

Recurrence in Patients with Breast Cancer. Clin

Cancer Res. 2016; 0f1 – of12.Available from

www.aacrjournals.org.DOI: 10.1158/1078-

CCR-16-2217.

Open Access Baghdad Science Journal P-ISSN: 2078-8665

, 18(4): 1140-1148 E-ISSN: 2411-7986

Nuttall FQ.Body Mass Index Obesity, BMI, and

Health: A Critical Review. Nutr Today. 2015; 50 (3):

– 128. Available from

www.nutritiontodayonline.com.DOI:

1097/NT.0000000000000092.

Mahir W, Rouas L, Ouzir M, Ferhati D, Rhrab

B, Alhamany Z, Cherradi N. Correlation of ER, PR

and HER2 with clinico-pathological parameters in

Infiltrating Ductal Carcinoma of Breast in Morocco

.Int J of Innovation and Applied Studies.2016; 14 (2)

: 498 – 506.

Arafah M. Correlation of Hormone Receptors with

Her-2 Neu Protein Expression and the Histological

Grade in Invasive Breast Cancers in a Cohort of

Saudi Arabia.Turkish J of Pathol. 2012; 28 (1): 38 –

Available from http://www.endocrinology-

journals.org.DOI: 10.5146/tjpath.2012.01095.

Horwitz KB, McGuire WL.Estrogen control of

progesterone receptor in human breast cancer

correlation with nuclear processing of estrogen

receptor. The J ofbiol Chem. 1978; 253 (7): 2223 –

Dubowy RL, Feinberg RF, Keefe DL, Doncel

GF, Williams ShC, McSweet JC, et al . Improved

endometrial assessment using cyclin E and p27.

Fertility and Sterility.2003; 80 (1): 146 – 156. DOI:

1016/S0015-0282(03)00573-9.